---
document_datetime: 2025-05-07 13:56:52
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/evenity-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: evenity-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 15.3157091
conversion_datetime: 2025-12-21 11:17:33.999478
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Evenity

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA /  | This was an application for a group of | 12/05/2025                          | N/A                                         |                                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000268130   | variations.   |
|---------------------|---------------|

<div style=\"page-break-after: always\"></div>

|                                       | specified in the technical dossier) - Accepted A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted   |            |     |    |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----|
| Article 61(3) / EMA/N/0000268076      | - Notification acc. Article 61(3) - Update of the package leaflet with revised contact details of local representative.                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 06/05/2025 |     | PL |
| Variation type IB / EMA/VR/0000248627 | B.I.b) Control of active substance - B.I.b.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 18/02/2025 | N/A |    |
| Variation type IB / EMA/VR/0000245496 | C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template                                                                                                                                                                                                                                                                                                                                                                                        | 14/02/2025 | N/A |    |

<div style=\"page-break-after: always\"></div>

| change) - Accepted                                                                         |
|--------------------------------------------------------------------------------------------|
| C.I.11.z (IB) - To provide a new RMP version to update the submission of the final CSR for |
| study \"European non-interventional PASS                                                    |
| romosozumab by the EU-ADR Alliance                                                         |
| (OP0006)\" from \"year after the                                                             |
| interim                                                                                    |
| report from year 4 (2024)\" to \"Dec 2025\".                                                  |
| Furthermore, the Marketing Authorisation                                                   |
| introduce editorial changes.                                                               |